{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:53:36Z","timestamp":1791348816463,"version":"4.3.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Ministry of Health","award":["GR-2009-1483560"],"award-info":[{"award-number":["GR-2009-1483560"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.clinthera.2013.11.006","type":"journal-article","created":{"date-parts":[[2013,12,17]],"date-time":"2013-12-17T17:45:22Z","timestamp":1387302322000},"page":"128-140","source":"Crossref","is-referenced-by-count":76,"title":["Molecular Therapeutic Strategies for Spinal Muscular Atrophies: Current and Future Clinical Trials"],"prefix":"10.1016","volume":"36","author":[{"given":"Chiara","family":"Zanetta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Nizzardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Monguzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nereo","family":"Bresolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo P.","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2013.11.006_bib1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ajmg.10425","article-title":"Genetic risk assessment in carrier testing for spinal muscular atrophy","volume":"110","author":"Ogino","year":"2002","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.clinthera.2013.11.006_bib2","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/MOP.0b013e32833f3046","article-title":"Spinal muscular atrophy: a time for screening","volume":"22","author":"Prior","year":"2010","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.clinthera.2013.11.006_bib3","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/344540a0","article-title":"Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3","volume":"344","author":"Brzustowicz","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2013.11.006_bib4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.clinthera.2013.11.006_bib5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0960-8966(06)80015-5","article-title":"International SMA consortium meeting (26-28 June 1992, Bonn, Germany)","volume":"2","author":"Munsat","year":"1992","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.clinthera.2013.11.006_bib6","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Wang","year":"2007","journal-title":"J Child Neurol"},{"key":"10.1016\/j.clinthera.2013.11.006_bib7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1750-1172-6-71","article-title":"Spinal muscular atrophy","volume":"6","author":"D\u2019Amico","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clinthera.2013.11.006_bib8","doi-asserted-by":"crossref","first-page":"e5268","DOI":"10.1371\/journal.pone.0005268","article-title":"Phase II open label study of valproic acid in spinal muscular atrophy","volume":"4","author":"Swoboda","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2013.11.006_bib9","doi-asserted-by":"crossref","first-page":"e12140","DOI":"10.1371\/journal.pone.0012140","article-title":"Project Cure Spinal Muscular Atrophy Investigators Network. SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy","volume":"5","author":"Swoboda","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2013.11.006_bib10","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/jmg.2010.080366","article-title":"Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design","volume":"47","author":"Tiziano","year":"2010","journal-title":"J Med Genet"},{"key":"10.1016\/j.clinthera.2013.11.006_bib11","doi-asserted-by":"crossref","first-page":"e21296","DOI":"10.1371\/journal.pone.0021296","article-title":"Project Cure Spinal Muscular Atrophy Investigators\u2019 Network. SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy","volume":"6","author":"Kissel","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2013.11.006_bib12","doi-asserted-by":"crossref","unstructured":"Cano SJ, Mayhew A, Glanzman AM, et al. Rasch analysis of clinical outcome measures in spinal muscular atrophy. Muscle Nerve. 2013 Jul 8 [Epub ahead of print]","DOI":"10.1002\/mus.23937"},{"key":"10.1016\/j.clinthera.2013.11.006_bib13","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.nmd.2007.02.006","article-title":"The Hammersmith functional score correlates with the SMN2 copy number: a multicentric study","volume":"17","author":"Tiziano","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.clinthera.2013.11.006_bib14","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1399-0004.2009.01200.x","article-title":"Genotype-phenotype studies in infantile spinal muscular atrophy (SMA) type I in Germany: implications for clinical trials and genetic counselling","volume":"76","author":"Rudnik-Sch\u00f6neborn","year":"2009","journal-title":"Clin Genet"},{"key":"10.1016\/j.clinthera.2013.11.006_bib15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1474-4422(12)70061-3","article-title":"Childhood spinal muscular atrophy: controversies and challenges","volume":"11","author":"Mercuri","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2013.11.006_bib16","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1172\/JCI57291","article-title":"Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy","volume":"121","author":"Lutz","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2013.11.006_bib17","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ana.20473","article-title":"Natural history of denervation in SMA: relation to age, SMN2 copy number, and function","volume":"57","author":"Swoboda","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinthera.2013.11.006_bib18","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1124\/jpet.107.123000","article-title":"Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis","volume":"322","author":"Bordet","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2013.11.006_bib19","unstructured":"ClinicalTrial.gov. Safety and efficacy of olesoxime (TRO19622) in 3-25 years SMA patients. http:\/\/clinicaltrials.gov\/show\/NCT01302600. Accessed October 8, 2013."},{"key":"10.1016\/j.clinthera.2013.11.006_bib20","unstructured":"Trophos. Therapeutic programs, spinal muscular atrophy. http:\/\/www.trophos.com\/research\/spinal.htm. Accessed June 15, 2013."},{"key":"10.1016\/j.clinthera.2013.11.006_bib21","unstructured":"Families of Spinal Muscular Atrophy (FSMA). http:\/\/www.fsma.org. Accessed October 8, 2013."},{"key":"10.1016\/j.clinthera.2013.11.006_bib22","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1089\/hum.2012.225","article-title":"Antisense oligonucleotides for the treatment of spinal muscular atrophy","volume":"24","author":"Porensky","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.clinthera.2013.11.006_bib23","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev"},{"key":"10.1016\/j.clinthera.2013.11.006_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001777","article-title":"Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy","volume":"3","author":"Passini","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clinthera.2013.11.006_bib25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature10485","article-title":"Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model","volume":"478","author":"Hua","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2013.11.006_bib26","unstructured":"ClinicalTrial.gov. An open-label safety, tolerability, and dose-range finding study of ISIS SMNRx in patients with spinal muscular atrophy. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01494701. Accessed October 7, 2013"},{"key":"10.1016\/j.clinthera.2013.11.006_bib27","unstructured":"Isis Pharmaceuticals. http:\/\/www.isispharm.com\/index.htm. Accessed October 7, 2013."},{"key":"10.1016\/j.clinthera.2013.11.006_bib28","unstructured":"ClinicalTrial.gov. An open-label safety and tolerability study of ISIS SMNRx in patients with spinal muscular atrophy who previously participated in ISIS 396443-CS1. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01780246. Accessed October 7, 2013."},{"key":"10.1016\/j.clinthera.2013.11.006_bib29","unstructured":"ClinicalTrial.gov. An open-label safety, tolerability and dose-range finding study of multiple doses of ISIS SMNRx in patient with spinal muscular atrophy (SMNRx-CS2). (http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01703988. Accessed September 15, 2013."},{"key":"10.1016\/j.clinthera.2013.11.006_bib30","unstructured":"ClinicalTrial.gov. A study to assess the safety and pharmacokinetics of ISIS SMNRx in infants with spinal muscular atrophy. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01839656. Accessed October 6, 2013."},{"key":"10.1016\/j.clinthera.2013.11.006_bib31","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1021\/cb800120t","article-title":"DcpS as a therapeutic target for spinal muscular atrophy","volume":"3","author":"Singh","year":"2008","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.clinthera.2013.11.006_bib32","first-page":"2003","article-title":"Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy Hum","volume":"14","author":"Jarecki","year":"2005","journal-title":"Mol Genet"},{"key":"10.1016\/j.clinthera.2013.11.006_bib33","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1021\/jm061475p","article-title":"Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy","volume":"51","author":"Thurmond","year":"2008","journal-title":"J Med Chem"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813011004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813011004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T00:54:07Z","timestamp":1538960047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291813011004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0149291813011004"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2013.11.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}